Ipsen telegraphed plans to acquire Epizyme and the FDA-approved Tazverik in June 2022, two years after the med’s clearance in the U.S. as both an epithelioid sarcoma and follicular lymphoma treatment.

Incyte announced Friday that the FDA issued a complete response letter for its PD-1 inhibitor Zynyz as a first-line treatment for non-small cell lung cancer.

Tommy DeCarlo, who sang with the band Boston for nearly 20 years after posting a Myspace tribute to the band’s original singer, has died at 60. On Monday, DeCarlo’s children said he died ...

Brenna Huckaby and her snowboard have been showstoppers at the Milan Cortina Paralympic Games. There’s Huckaby in glitter and ...

Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting ...

The Microfluidics Market has emerged as one of the most transformative segments within modern biotechnology, diagnostics, and pharmaceutical research. Microfluidics refers to the technology that ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies. However, nearly half of patients show limited ...

Patients with advanced cancer should be involved in decisions about their own treatment. Yet, patients, and relatives and ...

Cancer immunotherapies often rely on activating immune responses, yet many tumors remain resistant because their internal survival mechanisms are ...